Physician profile
Festus B Dada
NPI 1184632606
$995.94
in general payments reported to CMS, 2019-2025
17 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $28.90 · 2021: $72.12 · 2022: $142 · 2024: $117 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $121.35 | 2019 | |
| Davol INC. | $110.82 | 2021-2025 | Phasix Mesh |
| Angiodynamics, INC. | $105.00 | 2019 | |
| Kci USA, INC. | $76.48 | 2022 | |
| Biotissue Holdings INC. | $70.90 | 2024 | |
| Distalmotion US | $62.78 | 2025 | Dexter L6 Robot |
| Covidien LP | $60.67 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $58.54 | 2025 | |
| Acera Surgical, INC. | $56.38 | 2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $53.42 | 2019-2024 | Contour, Echelon Flex |
| Olympus America INC. | $51.45 | 2019-2022 | |
| Innocoll Pharmaceuticals Limited | $48.77 | 2021-2022 | |
| Mimedx Group, INC. | $33.79 | 2025 | |
| Baxter Healthcare | $27.86 | 2024 | Perclot |
| Leica Microsystems INC. | $21.29 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $19.16 | 2022 | |
| Conmed Corporation | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Festus Dada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.